Finance

Lists
HROW:NASDAQ
Harrow Inc
30,58 US$
+0,33%
(+0,10) 1D
31,19 US$
+1,99% (+0,61)
After hours
Closed: 5 ოქტ, 16:00:02 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HROW...
Open
31,43 US$
High
31,43 US$
Low
30,43 US$
Mkt. cap
1,15 მლრდ.
Avg. vol.
538,19 ათ.
Volume
0,00
52-wk high
54,85 US$
52-wk low
28,54 US$
EPS
-1,00 US$
Beta
0,19
Shares outstanding
37,49 მლნ.
No. of employees
373
Open
31,43 US$
High
31,43 US$
Low
30,43 US$
Mkt. cap
1,15 მლრდ.
Avg. vol.
538,19 ათ.
Volume
0,00
52-wk high
54,85 US$
52-wk low
28,54 US$
EPS
-1,00 US$
Beta
0,19
Shares outstanding
37,49 მლნ.
No. of employees
373
News stories
From web sources and news partners
The Business Journals
The Business Journals
·
11 საათის წინ
Harrow invests $30 million in new pharmaceutical as it builds portfolio
AD HOC NEWS
AD HOC NEWS
·
13 საათის წინ
Harrow Health stock gets TYRVAYA after USD 30 million deal
Profile
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing. In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary. Wikipedia
About Harrow Inc
CEOმარკ ელ ბაუმ ესკ
Employees373
Founded2012
Headquartersნეშვილი, ტენესი, ამერიკის შეერთებული შტატები
SectorPharmaceutical industry
Websiteharrow.com
Analyst ratings
Based on 8 analysts giving stock ratings to HROW in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for HROW in the last 3 months.
Highest
Current 30,58 US$
88,00 US$ (+187,77%)
Average
64,33 US$ (+110,37%)
Lowest
45,00 US$ (+47,16%)
Analyst
Recommendation
Action
Price target
Projected
Date
Thomas Flaten
Lake Street
Buy
Maintained
60,00 US$
+96,2%
10/05/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
10/05/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
-
-
09/29/2026
Daniel Clark
Leerink Partners
Buy
Initiated
45,00 US$
+47,2%
09/09/2026
Thomas Shrader
BTIG
Buy
Maintained
63,00 US$
+106%
08/25/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
70,00 US$
+128,9%
08/12/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
88,00 US$
+187,8%
08/10/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
60,00 US$
+96,2%
08/10/2026
Jeffrey Cohen
Ladenburg Thalmann & Co.
Buy
Reiterated
62,00 US$
+102,7%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
71,64 მლნ.
89,09 მლნ.
44,20 მლნ.
70,66 მლნ.
Cost of goods sold
17,71 მლნ.
18,47 მლნ.
17,16 მლნ.
20,30 მლნ.
Cost of revenue
17,71 მლნ.
18,47 მლნ.
17,16 მლნ.
20,30 მლნ.
Research and development expenses
3,32 მლნ.
11,72 მლნ.
5,90 მლნ.
8,07 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
35,86 მლნ.
43,31 მლნ.
43,23 მლნ.
53,30 მლნ.
Operating expense
39,18 მლნ.
55,03 მლნ.
49,12 მლნ.
61,37 მლნ.
Total operating expenses
56,89 მლნ.
73,50 მლნ.
66,28 მლნ.
81,67 მლნ.
Operating income
14,75 მლნ.
15,59 მლნ.
-22,08 მლნ.
-11,01 მლნ.
Other non operating income
61,00 ათ.
-8,00 ათ.
-
-
EBT including unusual items
1,02 მლნ.
10,40 მლნ.
-27,58 მლნ.
-17,27 მლნ.
EBT excluding unusual items
8,77 მლნ.
10,40 მლნ.
-27,58 მლნ.
-17,27 მლნ.
Income tax expense
-
3,77 მლნ.
25,00 ათ.
-
Effective tax rate
-
36,27%
-0,09%
-
Other operating expenses
-
-
-
-
Net income
1,02 მლნ.
6,63 მლნ.
-27,60 მლნ.
-17,27 მლნ.
Net profit margin
1,42%
7,44%
-62,44%
-24,44%
Earnings per share
0,33
0,27
-0,74
-0,46
Interest and investment income
-
-
-
-
Interest expense
-6,04 მლნ.
-5,19 მლნ.
-5,50 მლნ.
-6,26 მლნ.
Net interest expenses
-6,04 მლნ.
-5,19 მლნ.
-5,50 მლნ.
-6,26 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
19,31 მლნ.
20,22 მლნ.
-16,50 მლნ.
-5,02 მლნ.
Gain or loss from assets sale
-
13,00 ათ.
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები